Category Archives: Regenerative Medicine

Cord Blood Registry is Advancing Regenerative Medicine Research at Exciting Pace

Posted: March 20, 2013 at 9:52 am

SAN BRUNO,Calif., March 19, 2013 /PRNewswire/ --Cord Blood Registry (CBR), the world's largest newborn stem cell bank, is fueling innovation in newborn stem cell research. As CBR prepares to release its 250th cord blood unit for medical use this month, the newborn stem cell bank announces that 71% of all its units released for use have been for emerging applications in regenerative medicine, such as brain injury, autism and type 1 diabetes. The other 29% have been for traditional transplant use, such as leukemia and sickle cell disease. This rapid increase in the use of family banked units for regenerative medicine applications is a complete reversal from the figures just six years ago, where 25% of the units released were for regenerative medicine applications and 75% for traditional transplant use. More than 50% of all cord blood units released for use in emerging regenerative therapies by family banks have been processed and stored at CBR. CBR is the only family newborn stem cell bank to have established FDA-regulated trials and is connecting client families to more potential treatments. As the industry leader in this initiative, Cord Blood Registry continues to focus on advancing the clinical applications of newborn stem cells.

(Photo: http://photos.prnewswire.com/prnh/20130319/SF78273-INFO)

(Logo: http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO)

Over the past 20 years, cord blood stem cells have been used to treat more than 80 life-threatening diseases and disorders including certain cancers, blood disorders, immune diseases, and metabolic disorders. Today, promising treatments are paving the way for further research. Current FDA-regulated clinical trials are exploring the use of a child's own cord blood stem cells in regenerative medicine for conditions that have no cure today. Most of these groundbreaking trials only use cord blood stem cells processed and stored by Cord Blood Registry for consistency and because of their commitment to quality.

"At an increased pace, CBR is providing families exclusive access to promising new potential treatment options through our focus on clinical trials," said Geoffrey Crouse, CEO of Cord Blood Registry. "We are proud to partner with researchers at the forefront of stem cell medicine."

Clinical Trials Break New Ground in Regenerative Medicine

Cord blood stem cells are currently being evaluated in a series of clinical trials exclusive to CBR clients as potential treatment for autism, cerebral palsy, traumatic brain injury and pediatric stroke. Results will be published upon the completion of the trials.

Dr. Michael Chez, director of pediatric neurology at Sutter Medical Center, is leading a landmark FDA-regulated clinical trial to test the use of a child's own cord blood stem cells as a potential therapy to improve language and behavior in children with autism who have no obvious cause for the condition such as a known genetic syndrome or brain injury.

Dr. James Carroll at Georgia Regents University is conducting the first FDA-regulated clinical trial evaluating the use of cord blood stem cell infusions to treat children with cerebral palsy. Drake Haynes, who suffered a stroke after birth and was later diagnosed with cerebral palsy, was infused with his own CBR processed stem cells. Drake's progress is constantly being monitored and he continues to see multiple physical therapists. His family reports anecdotal evidence of steady progress in Drake's speech and mobility. Drake's mother, Nikki Haynes, describes it as the "blinds being lifted." A second FDA-regulated trial for cerebral palsy is underway at Duke University. A number of CBR families are currently participating in this key research as well.

Dr. Charles Cox, professor of pediatric surgery at The University of Texas Health Science Center in Houston (UT Health), is leading an FDA-regulated trial studying the use of a child's own cord blood stem cells in the treatment of traumatic brain injury (TBI).

Posted in Regenerative Medicine | Comments Off

Regenerative Medicine Market to Catapult to Over $35 Billion by 2019

Posted: March 12, 2013 at 1:46 am

NEW YORK, NY--(Marketwire - Mar 11, 2013) - TriMarkPublications.com cites in its newly published "Regenerative Medicine Markets" report that the regenerative medicine market will catapult to over $35 billion by 2019. For more information, visit: http://www.trimarkpublications.com/regenerative-medicine-markets/.

Regenerative medicine (RM) can be categorized into three main modalities: tissue engineering, biomaterials and biomolecules, e.g., scaffolds, growth factors and stem cell therapy. Tissue-engineered bone products in the orthopedic segment will see steady growth, from $7.5 billion in 2012 to $3.29 billion in 2019. The up-and-coming cardiology and vascular products segment will also see substantial growth, reaching a market value of $3.29 over the forecast period.

The "Regenerative Medicine Markets" report covers:

The "Regenerative Medicine Markets" report examines companies manufacturing regenerative medicine equipment and supplies in the world. Companies covered include: Amorcyte, Ars Arthro, Axiogenesis, AxoGen, Bellicum, BetaStem, Bioheart, Biomet, BioMimetic, BioTissue, Biovest, BrainStorm Cell, California Stem Cell, Cardio3, Cellartis, CellSeed, Cellular, Chromocell, Cognate, Cook, Cytomedix, Cytonet, Cytori, DanDrit, Fibrocell, Forticell, Gamida, Harvest, Histogenics, Humacyte, Integra, Intercytex, iPierian, Japan Tissue Engineering, Kensey Nash, Kiadis, Life Cell, Living Cell, MaxCyte, MediStem, Mesoblast, MolMed, NanoCor, Neuralstem, NeuroNova, NewLink Genetics, Olympus Terumo, OncoMed, Opexa, Organogenesis, Orthovita, Osiris, Osteotech, Pervasis, Pluristem, Proneuronnologies, RegeneRx, ReNeuron, Revivicor, SanBio, Saneron, Sangamo, Stem Cell Authority, StemCells, Stemline, Stratetech, Synthecon, Tengion, Thermogenesis, TiGenics, Tissue Genesis, ViaCyte, Vistagen and Zen-Bio.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/regenerative-medicine-markets/.

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

See more here:
Regenerative Medicine Market to Catapult to Over $35 Billion by 2019

Posted in Regenerative Medicine | Comments Off

Induced pluripotent stem cells in degenerative disease research

Posted: February 28, 2013 at 4:51 am

Abstract

Induced pluripotent stem cells (iPSCs) were first created in 2006 when it was shown that four gene factors could be used to reprogramme somatic cells to a stem cell-like state. Using this protocol, scientists could have a large, ethical supply of stem cells for research. This article considers some of the uses of iPSCs in developing degenerative disease therapies and some of the hurdles yet to be overcome before iPSCs can be used clinically.

Stem cells are undifferentiated pluripotent cells that can give rise to any of the body’s cells. There are many different types of stem cells in the body, but they all share major characteristics including clonality and the ability to self-renew (Evans and Kaufman, 1981). There are numerous benefits of using stem cells in research including scientists’ ability to manipulate them into the desired differentiated cell type. Embryonic stem cells (ESCs), especially, have enabled research into degenerative human diseases and offer potential cures for many disease types. However, there are numerous ethical issues associated with ESCs due to their provenance. Differentiated adult tissue cells (somatic cells) have recently been shown to be reprogrammable, creating induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006). This process avoids many of the ethical issues associated with ESCs. This article will discuss the recent progresses made with using iPSCs and the challenges yet to be overcome.

The importance of stem cells in regenerative disease models

Degenerative diseases are characterised by the progressive loss of particular cell types. Some well known examples include Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. However, despite the frequency of degenerative diseases, research into degeneration has been hindered due to the lack of representative in vitro models. So far, research has relied on the pluripotent characteristics of ESCs and has shown that lab-grown ESCs have the potential to replace lost tissues, for example by differentiating into brain, nerve and bone tissues amongst others (Lin, 2011; Handschel et al., 2011).

In spite of the advantages of ESCs, there are limitations to their use. ESCs cannot be cultured in sufficient quantities for regenerative medicine, partly due to their provenance: obtaining cells from embryos raises major ethical issues.

As a consequence, recent research has focused on finding alternative methods of generating representative disease models. Many barriers have arisen such as mature neurones not being able to divide, immortalised cell lines not being truly pluripotent and adult stem cells already being committed to a particular cell type. In this case, the cells rarely survived the neuronal differentiation process (Peng and Zeng, 2011).

The discovery of iPSCs

In 2006, it was discovered that gene factors could be used to induce somatic cell reprogramming. It was shown that any adult mouse tissue cell can be reprogrammed to an iPSC using a set of four gene factors (Takahashi and Yamanaka, 2006). Just a year later, it was shown that the same four gene factors could also be used to genetically reprogramme human somatic cells (Takahashi et al., 2007). The four factors used by Takahashi and Yamanaka were Oct4, Sox2, Klf4 and c-Myc (OSKM), though later work successfully substituted Klf4 and c-Myc with Lin28 and Nanog respectively (giving OSLN).

This technique enabled scientists to culture iPSCs from any somatic cell, providing an unlimited supply of stem cells. Additionally, ESCs and iPSCs have been shown to share many characteristics including morphology, proliferation, gene expression and surface antigens (Takahashi et al., 2007; Kolios and Moodley, 2013). The reprogramming process bypasses the ethical issues and the quantitative limitations of ESCs. Disease-specific models can now be cultured, overcoming many limitations of previously available systems (Peng and Zeng, 2011).

Brief overview of the steps for reprogramming

Reprogramming is initiated by introducing the four factors, OSKM or OSLN, into mature adult somatic cells. These factors bind in a specific order to their targets and induce the cellular stress response to viruses and oncogenes. This in turn recruits p53, which is crucial in ensuring that only cells with genomic integrity survive to the pluripotent stage. It has been shown that c-Myc is fundamental in both the early stages of translation and in decreasing expression of mouse embryonic fibroblasts (MEF)-enriched miRNAs, which are barriers to reprogramming (Yang and Rana, 2013).

The next step in reprogramming is mesenchymal-to-epithelial (MET) transition, which is essential for some cells to start their de-differentiation process. During MET transition, the reprogrammed cells start to display pluripotency markers. Of these markers, SSEA-1 is the first to be expressed and indicates potential iPSCs. The expression of additional factors mark a successful and complete reprogramming (Yang and Rana, 2013).

The potential for iPSCs

The unlimited supply and differentiation capacities of iPSCs means models of many diseases can now be created for research. These models enable scientists to gain a better understanding of the mechanisms of diseases, potentially leading to cell-based therapy.

Another major clinical opportunity for iPSCs is tolerance to treatment. Somatic cells can be taken and reprogrammed from the person requiring treatment, meaning a personalised diagnosis and the conservation of their specific cell markers. This should prevent immune rejection (Park et al., 2008). Disease models are expected to be more accurate with iPSCs; as the cells are taken directly from the diseased patients, the genetic makeup of the disease can be conserved (Dimos et al., 2008).

Drug development is another area made easier with iPSCs. Reprogramming means large quantities of pluripotent stem cells. iPSCs can be created as long as researchers have access to adult somatic cells. Drug development requires numerous assays and an increase in the quantity of pluripotent stem cells is invaluable for progress. Furthermore the reprogramming protocol is fairly straightforward (Oh et al., 2012). However, it should be noted that, at present, it is not yet known how iPSCs would behave in a clinical environment compared to ESCs (Kolios and Moodley, 2013).

Limitations to iPSC use: safety concerns

The main iPSC safety concern is genetic stability. The use of retroviral vectors and oncogenes such as c-Myc and Klf4 are a major cause of concern for clinical studies. The transcription factors are typically introduced into the somatic cells using vectors, generating a possibility of cancer formation (Kolios and Moodley, 2013; Okita et al., 2007).

There are new techniques emerging that prevent genetic instability. Reprogramming can be achieved using just two of the four gene factors mentioned. Oct4 and Soc2 can induce reprogramming without the other oncogenic factors in the presence of a histone deacetylase inhibitor (Huangfu et al., 2008).

Alternatively, microRNAs, along with Oct4, Sox2 and Klf4, can induce reprogramming and actually increase the rate of efficiency with respect to the OSKM factors alone. New viral vectors and recombinant proteins have also been considered as alternatives to the OSKM factors (Ebben et al., 2011).

Limitations to iPSC use: supply concerns

As research progresses, the main provenance of iPSCs will likely be from diseased patients’ somatic cells. This will make iPSCs much more easily available than ESCs, but will not necessarily solve supply problems completely. Reprogramming is not an efficient process, and many somatic cells do not complete it (Polo et al., 2012). Stem cells are also known for their delicacy and specific culture requirements. A lot of laboratory equipment is too abrasive for stem cells and is susceptible to regularly blocking. This said, recent progress in automated liquid handlers design means that robots capable of handling stem cells do now exist (e.g. Redd&Whyte’s Preddator).

Conclusions

Since the first creation of iPSCs in 2006, research has come a long way. We are now able to create patient-specific and disease-specific degenerative disease models. However, before clinical trials with iPSCs can occur, some important barriers remain to be overcome. The full potential of iPSCs to improve our understanding of diseases is not yet clear, but progress in this field is clearly happening quickly.

About The Author: Clare Stewart is a biochemistry student at the University of Manchester, she has written this post on behalf of Redd & Whyte

References:

Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitsumoto, H., Chung, W., Croft, G. F., Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C. E. & Eggan, K. (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 321(5893), 1218-1221.

Ebben, J. D., Zorniak, M., Clark, P. A. & Kuo, J. S. (2011) Introduction to Induced Pluripotent Stem Cells: Advancing the Potential for Personalized Medicine. World Neurosurgery, 76(3-4), 270-275.

Evans, M. J. & Kaufman, M. H. (1981) Establishment In Culture Of Pluripotential Cells From Mouse Embryos. Nature, 292(5819), 154-156.

Handschel, J., Naujoks, C., Depprich, R., Lammers, L., Kubler, N., Meyer, U. & Wiesmann, H. P. (2011) Embryonic stem cells in scaffold-free three-dimensional cell culture: osteogenic differentiation and bone generation. Head & Face Medicine, 7.

Huangfu, D. W., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W. & Melton, D. A. (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotechnology, 26(11), 1269-1275.

Kolios, G. & Moodley, Y. (2013) Introduction to Stem Cells and Regenerative Medicine. Respiration, 85(1), 3-10.

Lin, S. L. (2011) Concise Review: Deciphering the Mechanism Behind Induced Pluripotent Stem Cell Generation. Stem Cells, 29(11), 1645-1649.

Oh, Y. Z., Wei, H. M., Ma, D. R., Sun, X. M. & Liew, R. (2012) Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart, 98(6), 443-449.

Okita, K., Ichisaka, T. & Yamanaka, S. (2007) Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313-U1.

Park, I. H., Lerou, P. H., Zhao, R., Huo, H. G. & Daley, G. Q. (2008) Generation of human-induced pluripotent stem cells. Nature Protocols, 3(7), 1180-1186.

Peng, J. & Zeng, X. M. (2011) The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. Stem Cell Research & Therapy, 2.

Polo, J. M., Anderssen, E., Walsh, R. M., Schwarz, B. A., Nefzger, C. M., Lim, S. M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., Bar-Nur, O., Cheloufi, S., Stadtfeld, M., Figueroa, M. E., Robinton, D., Natesan, S., Melnick, A., Zhu, J. F., Ramaswamy, S. & Hochedlinger, K. (2012) A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells. Cell, 151(7), 1617-1632.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. & Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.

Takahashi, K. & Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.

Yang, C. S. & Rana, T. M. (2013) Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs. Molecular Biosystems, 9(1), 10-17.

Posted in Regenerative Medicine, Stem Cells | Comments Off

New Study at the Center for Regenerative Medicine – Mayo Clinic – Video

Posted: February 20, 2013 at 1:47 pm

New Study at the Center for Regenerative Medicine - Mayo Clinic
The Center for Regenerative Medicine at Mayo Clinic investigates what advances of stem cell biology would be useful to apply in the treatment of patients with end stage diseases. Jorge Rakela, MD, associate director for the Center, provides an overview of the Center which is also involved in a tissue engineering program with Arizona State University. Jeffery Cornella, MD, a gynecological surgeon at Mayo Clinic, and Johnny Yi, MD, a surgical fellow at Mayo Clinic, talk about a study underway to develop new tissue to aid in the treatment of vaginal prolapse and other conditions.

By: mayoclinic

Follow this link:
New Study at the Center for Regenerative Medicine - Mayo Clinic - Video

Posted in Regenerative Medicine | Comments Off

Regenerative medicine and Stem cells Partnering Terms and Agreements

Posted: February 20, 2013 at 1:47 pm

NEW YORK, Feb. 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative medicine and Stem cells Partnering Terms and Agreements http://www.reportlinker.com/p01098514/Regenerative-medicine-and-Stem-cells-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in regenerative medicine and stem cells deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2008 including financial terms where available including over 550 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

See the original post here:
Regenerative medicine and Stem cells Partnering Terms and Agreements

Posted in Regenerative Medicine | Comments Off

Introduction to the Stanford Institute for Stem Cell Biology and Regenerative Medicine – Video

Posted: February 14, 2013 at 8:42 pm

Introduction to the Stanford Institute for Stem Cell Biology and Regenerative Medicine
Institute stem cell researchers Michael Longaker, Ravi Majeti, Renee Reijo Pera, Michael Clarke and Maximilian Diehn talk about research on regenerative medicine, cancer therapies and reproduction, and how clinical experiences motivate them to work even harder to find new therapies for disease.

By: institutesofmedicine

Posted in Regenerative Medicine | Comments Off

JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte

Posted: February 13, 2013 at 11:47 am

-- Treatment being developed would use encapsulation to protect new insulin-producing cells derived from a stem cell precursor --

NEW YORK and SAN FRANCISCO, Feb. 13, 2013 /PRNewswire-USNewswire/ --JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, announced that they are providing additional funding for the development of a novel stem cell therapy by San Diego-based ViaCyte, Inc.; JDRF and CIRM will each contribute $3 million to further advance the project.

"One of the most important elements in bringing promising therapies to clinical trials is a strong partnership, and that's what we have with CIRM, JDRF, and ViaCyte," saidEllen Feigal, M.D., senior vice president for research and development at CIRM. "Working together, we can help ensure that the most promising therapies stay on course for timely entry into clinical trials. This additional commitment of funding and support by JDRF is a reflection of the hope we all have that this therapy will transform the lives of people with type 1 diabetes."

ViaCyte's innovative product is designed to deliver to patients immature pancreatic progenitor cells developed from a human embryonic stem cell (hESC) line; over time, these cells develop into mature pancreatic cells that are capable of producing pancreatic hormones, including insulin. These cells are encapsulated in a device that isolates the cells from the host but allows free flow of oxygen, nutrients, and other factors, so that the cells can respond to blood glucose and release hormones like insulin while being protected from the patient's immune system. The combination product is designated VC-01. The benefit of such a breakthrough would be the ability to provide a patient with a new source of insulin-producing cells to replace those destroyed by the autoimmune response that is a hallmark of T1D.

"The research being performed by ViaCyte is very promising," said Julia Greenstein, Ph.D., JDRF's vice president of cure therapies. "The ability to encapsulate and thereby protect implanted insulin-producing cells has been a focus for JDRF because of its potential to solve multiple problems at once. ViaCyte is currently at the forefront of developing this technology, making this a very attractive research opportunity for us."

The contributions by JDRF and CIRM are intended to move ViaCyte's combination of stem cell-derived pancreatic progenitors and encapsulation device (VC-01 combination product) to approval by the U.S. Food and Drug Administration (FDA) for proof of concept human clinical trials. To date, VC-01 has been shown to be effective in controlling blood glucose in multiple preclinical models, and clinical trials to initially investigate the safety and efficacy in patients with T1D are expected to be initiated next year.

Dr. Paul Laikind, ViaCyte's chief executive officer and president, said, "CIRM and JDRF are valuable partners as we pursue this potentially transformative new approach to controlling insulin-dependent diabetes. While we appreciate their financial awards, we have also benefited from the valuable technical support and advocacy they provide to our program. With their help we will soon determine if the promising results we have demonstrated in preclinical studies translate to patients. If so, VC-01 could essentially represent a cure for type 1 diabetes and an important therapy for patients with insulin-requiring type 2 diabetes."

Video Link ViaCyte's research and development of a cell encapsulation product holds the promise of a cure for people with T1D and their families. This CIRM produced video describes the work being supported at ViaCyte and explains it potential impact for those with T1D from the perspective of two families that support JDRF's mission.

About CIRM CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About JDRFJDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Link:
JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte

Posted in Regenerative Medicine | Comments Off

Julia Greenstein Regenerative Medicine and Stem Cell Biology – Video

Posted: February 12, 2013 at 5:47 pm

Julia Greenstein Regenerative Medicine and Stem Cell Biology
This clip is part of the Career Girls ongoing series of career guidance/inspiration videos. See more at http://www.careergirls.org

By: careergirls

Go here to read the rest:
Julia Greenstein Regenerative Medicine and Stem Cell Biology - Video

Posted in Regenerative Medicine | Comments Off

Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com

Posted: February 12, 2013 at 5:47 pm

Dallas, TX (PRWEB) February 12, 2013

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multi component, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2008 including financial terms were available including over 550 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

The initial chapters of this report provide an orientation of drug deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells deal making since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all bio pharma companies.

More:
Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com

Posted in Regenerative Medicine | Comments Off

Researcher’s $375,000 regenerative medicine boost

Posted: February 6, 2013 at 8:49 pm

Body tissue engineer Jess Frith will determine the role of specific molecules in cell development in world-first research, with plans to use the knowledge to repair bones and cartilage.

Dr Frith, from The University of Queensland (UQ), will combine cells with biomaterials to reconstruct body tissues in the lab with the aim to one day potentially treating osteoporosis, osteoarthritis or intervertebral disc degeneration.

Her project, being undertaken at UQ's Australian Institute for Bioengineering and Nanotechnology, has received a boost from a $375,000 Australian Research Council (ARC) award.

The ARC Discovery Early Career Researcher Award will fund Dr Frith's research costs at AIBN's Tissue Engineering and Microfluidics Laboratory for the next three years.

I think regenerative medicine has the potential to transform medicine in the future but a major hurdle in achieving this is our ability to make cells behave as we want, Dr Frith said.

We are working with specific stem cells derived from people's bone marrow. They can be used to generate bone, cartilage, muscle and fat cells.

The cells need to turn into the correct tissue type. Controlling this is difficult. We know that stem cells are very sensitive to the environment around them.

Dr Frith plans to investigate whether molecules called microRNAs play an important role in how the response of cells to their environment determines cell development.

I will be using biomaterials to see if I can influence microRNAs and see if I can push stem cells to form specific tissues, she said.

Dr Frith said regenerative medicine was an exciting field because of the fast pace of advances that have been made during the past few years".

More here:
Researcher’s $375,000 regenerative medicine boost

Posted in Regenerative Medicine | Comments Off

Page 84«..10 20..838485 86..90 100..»

Category Archives: Regenerative Medicine

Cord Blood Registry is Advancing Regenerative Medicine Research at Exciting Pace

Regenerative Medicine Market to Catapult to Over $35 Billion by 2019

Induced pluripotent stem cells in degenerative disease research

New Study at the Center for Regenerative Medicine – Mayo Clinic – Video

Regenerative medicine and Stem cells Partnering Terms and Agreements

Introduction to the Stanford Institute for Stem Cell Biology and Regenerative Medicine – Video

JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte

Julia Greenstein Regenerative Medicine and Stem Cell Biology – Video

Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com

Researcher’s $375,000 regenerative medicine boost

Categories

Archives

Recommended Sites

Contact Us

Recent Posts